Analysis and variability of TGFβ measurements in cancer patients with skeletal metastases

Biologics: Targets and Therapy

Volumn 2, Issue 3, 2008, Pages 563-569

  O'Brien, Peter J ^a   Ramanathan, Rajeev ^b   Yingling, Jonathan M ^a   Baselga, Jose ^c   Rothenberg, Mace L ^d   Carducci, Michael ^e   Daly, Thomas ^a   Adcock, Dorothy ^b   Lahn, Michael ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Esoterix Inc   (United States)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Biomarker; Cancer; CTAD; TGF

Indexed keywords

EID: 77954176730     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Assoian RK, Sporn MB. 1986. Type beta transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J Cell Biol, 102:1217-23.
2. Baselga J, Rothenberg ML, Tabernero J, et al. TGF-β signaling related markers in cancer patients with bone metastasis. Biomarkers, 13:217-36.
3. Blobe GC, Schiemann WP, Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med, 342:1350-8.
4. Caine GJ, Stonelake PS, Lip GY, et al. 2002. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia (New York), 4:465-73.
5. Contant G, Gouault-Heilmann M, Martinoli JL. 1983. Heparin inactivation during blood storage: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-C.T.A.D. mixture. Thromb Res, 31:365-74.
6. Culhaci N, Sagol O, Karademir S, et al. 2005. Expression of transforming growth factor-beta-1 and p27Kip1 in pancreatic adenocarcinomas: relation with cell-cycle-associated proteins and clinicopathologic characteristics. BMC Cancer, 5:98.
7. Golanski J, Pietrucha T, Baj Z, et al. 1996. Molecular insights into the anticoagulant-induced spontaneous activation of platelets in whole blood - various anticoagulants are not equal. Thromb Res, 83:199-216.
8. Gordinier ME, Zhang HZ, Patenia R, et al. 1999. Quantitative analysis of transforming growth factor beta 1 and 2 in ovarian carcinoma. Clin Cancer Res, 5:2498-505.
9. Hazelbag S, Kenter GG, Gorter A, et al. 2004. Prognostic relevance of TGFbeta1 and PAI-1 in cervical cancer. Int J Cancer, 112:1020-8.
10. Kang Y, He W, Tulley S, et al. 2005. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA, 102:13909-14.
11. Kaplan KL, Owen J. 1981. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood, 57:199-202.
12. Kropf J, Schurek JO, Wollner A, et al. 1997. Immunological measurement of transforming growth factor-beta 1 (TGF-β1) in blood; assay development and comparison. Clin Chem, 43:1965-74.
13. Macey M, Azam U, McCarthy D, et al. 2002. Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem, 48:891-9.
14. Neufeld M, Nowak-Gottl U, Junker R. 1999. Citrate-theophylline-adeninedipyridamol buffer is preferable to citrate buffer as an anticoagulant for flow cytometric measurement of platelet activation. Clin Chem, 45:2030-3.
15. Nio Y, Omori H, Hashimoto K, et al. 2005. Immunohistochemical expression of receptor-tyrosine kinase c-kit protein and TGF-beta1 in invasive ductal carcinoma of the pancreas. Anticancer Res, 25:3523-9.
16. Philippe J, De Logi E, Baele G. 2004. Comparison of five different citrated tubes and their in vitro effects on platelet activation. Clin Chem, 50:656-8.
17. Reinhold D, Bank U, Buhling F, et al. 1997. A detailed protocol for the measurement of TGFb1 in human blood samples. J Immun Methods, 209:203-6.
18. Roberts AB, Wakefield LM. 2003. The two faces of transforming growth factor beta in carcinogenesis [comment]. Proc Natl Acad Sci USA, 100:8621-3.
19. Seyedin SM, Thomas TC, Thompson AY, et al. 1985. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc Natl Acad Sci USA, 82:2267-71.
20. Shariat SF, Shalev M, Menesses-Diaz A, et al. 2001. Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol, 19:2856-64.
21. Siegel PM, Massague J. 2003. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nature Rev Cancer, 3:807-21.
22. Wakefield LM, Letterio JJ, Chen T, et al. 1995. Transforming growth factorbeta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin Cancer Res, 1:129-36.
23. Yamamoto T, Akisue T, Marui T, et al. 2004. Expression of transforming growth factor beta isoforms and their receptors in malignant fibrous histiocytoma of soft tissues. Clin Cancer Res, 10:5804-7.
24. Zimmermann R, Koenig J, Zingsem J, et al. 2005. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem, 51:2365-8.